Logo image of ASTH

ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis

NASDAQ:ASTH - Nasdaq - US03763A2078 - Common Stock - Currency: USD

21.46  -0.35 (-1.6%)

After market: 23.69 +2.23 (+10.39%)

Fundamental Rating

5

ASTH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of ASTH get a neutral evaluation. Nothing too spectacular is happening here. ASTH is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ASTH had positive earnings in the past year.
ASTH had a positive operating cash flow in the past year.
In the past 5 years ASTH has always been profitable.
ASTH had a positive operating cash flow in each of the past 5 years.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

ASTH's Return On Assets of 2.63% is fine compared to the rest of the industry. ASTH outperforms 62.14% of its industry peers.
ASTH has a better Return On Equity (4.70%) than 60.19% of its industry peers.
ASTH has a Return On Invested Capital (5.19%) which is comparable to the rest of the industry.
ASTH had an Average Return On Invested Capital over the past 3 years of 7.07%. This is below the industry average of 9.38%.
Industry RankSector Rank
ROA 2.63%
ROE 4.7%
ROIC 5.19%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

With a decent Profit Margin value of 1.56%, ASTH is doing good in the industry, outperforming 60.19% of the companies in the same industry.
ASTH's Profit Margin has declined in the last couple of years.
ASTH has a Operating Margin (3.55%) which is in line with its industry peers.
In the last couple of years the Operating Margin of ASTH has declined.
ASTH has a worse Gross Margin (11.94%) than 72.82% of its industry peers.
In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 3.55%
PM (TTM) 1.56%
GM 11.94%
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASTH is destroying value.
ASTH has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ASTH has a worse debt to assets ratio.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 3.52 indicates that ASTH is not in any danger for bankruptcy at the moment.
ASTH has a better Altman-Z score (3.52) than 68.93% of its industry peers.
ASTH has a debt to FCF ratio of 8.01. This is a slightly negative value and a sign of low solvency as ASTH would need 8.01 years to pay back of all of its debts.
ASTH's Debt to FCF ratio of 8.01 is in line compared to the rest of the industry. ASTH outperforms 57.28% of its industry peers.
A Debt/Equity ratio of 0.54 indicates that ASTH is somewhat dependend on debt financing.
ASTH's Debt to Equity ratio of 0.54 is in line compared to the rest of the industry. ASTH outperforms 59.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 8.01
Altman-Z 3.52
ROIC/WACC0.6
WACC8.7%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

ASTH has a Current Ratio of 1.70. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
ASTH has a Current ratio of 1.70. This is comparable to the rest of the industry: ASTH outperforms 58.25% of its industry peers.
A Quick Ratio of 1.70 indicates that ASTH should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.70, ASTH is in the better half of the industry, outperforming 62.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.7
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

8

3. Growth

3.1 Past

The earnings per share for ASTH have decreased strongly by -64.58% in the last year.
The Earnings Per Share has been growing by 19.19% on average over the past years. This is quite good.
Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 46.72%.
Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
Revenue 1Y (TTM)46.72%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%

3.2 Future

ASTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.87% yearly.
ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.61% yearly.
EPS Next Y36.88%
EPS Next 2Y38.32%
EPS Next 3Y39.78%
EPS Next 5Y31.87%
Revenue Next Year46.79%
Revenue Next 2Y34.88%
Revenue Next 3Y27.66%
Revenue Next 5Y16.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 42.08, which means the current valuation is very expensive for ASTH.
The rest of the industry has a similar Price/Earnings ratio as ASTH.
ASTH is valuated expensively when we compare the Price/Earnings ratio to 26.54, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 12.60, the valuation of ASTH can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ASTH indicates a somewhat cheap valuation: ASTH is cheaper than 76.70% of the companies listed in the same industry.
ASTH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.28.
Industry RankSector Rank
PE 42.08
Fwd PE 12.6
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

ASTH's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ASTH is cheaper than 63.11% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASTH is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 20.56
EV/EBITDA 11.2
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ASTH's earnings are expected to grow with 39.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.14
PEG (5Y)2.19
EPS Next 2Y38.32%
EPS Next 3Y39.78%

More info and screens

0

5. Dividend

5.1 Amount

ASTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTRANA HEALTH INC

NASDAQ:ASTH (8/7/2025, 8:11:21 PM)

After market: 23.69 +2.23 (+10.39%)

21.46

-0.35 (-1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners53.66%
Inst Owner ChangeN/A
Ins Owners9.71%
Ins Owner Change-6.75%
Market Cap1.07B
Analysts83.53
Price Target48.39 (125.49%)
Short Float %3.94%
Short Ratio5.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP26.84%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-134.77%
Min EPS beat(2)-225.16%
Max EPS beat(2)-44.39%
EPS beat(4)2
Avg EPS beat(4)-66.81%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)6
Avg EPS beat(8)-18.15%
EPS beat(12)9
Avg EPS beat(12)-1.53%
EPS beat(16)12
Avg EPS beat(16)7.33%
Revenue beat(2)1
Avg Revenue beat(2)1.05%
Min Revenue beat(2)-3.56%
Max Revenue beat(2)5.66%
Revenue beat(4)3
Avg Revenue beat(4)2.94%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)8.16%
Revenue beat(8)4
Avg Revenue beat(8)0.79%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.68%
PT rev (3m)-5.97%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)10.39%
EPS NY rev (1m)8.39%
EPS NY rev (3m)-9.47%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-2.43%
Revenue NY rev (1m)8.3%
Revenue NY rev (3m)7.25%
Valuation
Industry RankSector Rank
PE 42.08
Fwd PE 12.6
P/S 0.48
P/FCF 20.56
P/OCF 17.05
P/B 1.44
P/tB 4.94
EV/EBITDA 11.2
EPS(TTM)0.51
EY2.38%
EPS(NY)1.7
Fwd EY7.93%
FCF(TTM)1.04
FCFY4.86%
OCF(TTM)1.26
OCFY5.87%
SpS45.07
BVpS14.93
TBVpS4.35
PEG (NY)1.14
PEG (5Y)2.19
Profitability
Industry RankSector Rank
ROA 2.63%
ROE 4.7%
ROCE 8.23%
ROIC 5.19%
ROICexc 7.1%
ROICexgc 27.85%
OM 3.55%
PM (TTM) 1.56%
GM 11.94%
FCFM 2.32%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexcg growth 3Y-13.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score5
Asset Turnover1.69
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 8.01
Debt/EBITDA 3.69
Cap/Depr 36.16%
Cap/Sales 0.48%
Interest Coverage 2.55
Cash Conversion 57.41%
Profit Quality 148.88%
Current Ratio 1.7
Quick Ratio 1.7
Altman-Z 3.52
F-Score5
WACC8.7%
ROIC/WACC0.6
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
EPS Next Y36.88%
EPS Next 2Y38.32%
EPS Next 3Y39.78%
EPS Next 5Y31.87%
Revenue 1Y (TTM)46.72%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
Revenue Next Year46.79%
Revenue Next 2Y34.88%
Revenue Next 3Y27.66%
Revenue Next 5Y16.61%
EBIT growth 1Y-13.63%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year96.88%
EBIT Next 3Y48.82%
EBIT Next 5Y30.85%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A